Rituximab Treatment in a Patient with Active Graves' Orbitopathy and Psoriasis.
Management of Graves' orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves' orbitopathy. Here we report a case of a 49-year-old woman with Graves' orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart. Although there was improvement in inflammatory signs of the disease, proptosis did not change after the treatment.
Eskişehir Osmangazi University Faculty of Medicine, Department of Ophthalmology, Eskişehir, Turkey.
Tülay
T
Şimşek
Eskişehir Osmangazi University Faculty of Medicine, Department of Ophthalmology, Eskişehir, Turkey.
Nilgün
N
Yıldırım
Eskişehir Osmangazi University Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology, Eskişehir, Turkey.
Belgin
B
Efe
Eskişehir Osmangazi University Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology, Eskişehir, Turkey.
Nur
N
Kebapçı
Graves’ orbitopathy; Psoriasis; Rituximab